Rathish Devarajan, Bahini Sivaswamy, Sivakumar Thanikai, Thiranagama Thilani, Abarajithan Tharmarajah, Wijerathne Buddhika, Jayasumana Channa, Siribaddana Sisira
Department of Pharmacology, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura, Sri Lanka.
Department of Physiology, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura, Sri Lanka.
BMC Pharmacol Toxicol. 2016 Jun 25;17(1):27. doi: 10.1186/s40360-016-0071-z.
Prescription writing is a process which transfers the therapeutic message from the prescriber to the patient through the pharmacist. Prescribing errors, drug duplication and potential drug-drug interactions (pDDI) in prescriptions lead to medication error. Assessment of the above was made in prescriptions dispensed at State Pharmaceutical Corporation (SPC), Anuradhapura, Sri Lanka.
A cross sectional study was conducted. Drugs were classified according to the WHO anatomical, therapeutic chemical classification system. A three point Likert scale, a checklist and Medscape online drug interaction checker were used to assess legibility, completeness and pDDIs respectively.
Thousand prescriptions were collected. Majority were hand written (99.8 %) and from the private sector (73 %). The most frequently prescribed substance and subgroup were atorvastatin (4 %, n = 3668) and proton pump inhibitors (7 %, n = 3668) respectively. Out of the substances prescribed from the government and private sectors, 59 and 50 % respectively were available in the national list of essential medicines, Sri Lanka. Patients address (5 %), Sri Lanka Medical Council (SLMC) registration number (35 %), route (7 %), generic name (16 %), treatment symbol (48 %), diagnosis (41 %) and refill information (6 %) were seen in less than half of the prescriptions. Most were legible with effort (65 %) and illegibility was seen in 9 %. There was significant difference in omission and/or errors of generic name (P = 0.000), dose (P = 0.000), SLMC registration number (P = 0.000), and in evidence of pDDI (P = 0.009) with regards to the sector of prescribing. The commonest subgroup involved in duplication was non-steroidal anti-inflammatory drugs (NSAIDs) (43 %; 56/130). There were 1376 potential drug interactions (466/887 prescriptions). Most common pair causing pDDI was aspirin with losartan (4 %, n = 1376).
Atorvastatin was the most frequently prescribed substance. Fifteen percent of the prescriptions originate from government sector. SLMC registration number and trade names were seen more in prescriptions originating from the private sector. Most prescriptions were legible with effort. NSAIDs were the commonest implicated in drug class duplication. Fifty three percent of prescriptions have pDDI.
处方开具是一个将治疗信息从开处方者通过药剂师传递给患者的过程。处方中的开方错误、药物重复和潜在药物相互作用(pDDI)会导致用药错误。对斯里兰卡阿努拉德普勒国家制药公司(SPC)配出的处方进行了上述情况的评估。
进行了一项横断面研究。药物根据世界卫生组织解剖学、治疗学和化学分类系统进行分类。分别使用三点李克特量表、检查表和Medscape在线药物相互作用检查器来评估处方的易读性、完整性和pDDI。
收集了1000份处方。大多数是手写的(99.8%),来自私营部门(73%)。最常开具的药物和亚组分别是阿托伐他汀(4%,n = 3668)和质子泵抑制剂(7%,n = 3668)。在政府和私营部门开具的药物中,分别有59%和50%可在斯里兰卡基本药物国家清单中找到。不到一半的处方中有患者地址(5%)、斯里兰卡医学委员会(SLMC)注册号(35%)、给药途径(7%)、通用名(16%)、治疗符号(48%)、诊断(41%)和续方信息(6%)。大多数处方费力可读(65%),9%难以辨认。在通用名(P = 0.000)、剂量(P = 0.000)、SLMC注册号(P = 0.000)以及pDDI证据(P = 0.009)方面,不同开方部门存在显著差异。涉及重复的最常见亚组是非甾体抗炎药(NSAIDs)(43%;56/130)。有1376种潜在药物相互作用(466/887份处方)。导致pDDI最常见的药物对是阿司匹林与氯沙坦(4%,n = 1376)。
阿托伐他汀是最常开具的药物。15%的处方来自政府部门。SLMC注册号和商品名在来自私营部门的处方中出现得更多。大多数处方费力可读。NSAIDs是药物类别重复中最常见的涉及药物。53%的处方存在pDDI。